Jobs
-
A number of companies that provide products and services for inhaled and nasal drugs had booths at the 2012 AAPS annual meeting. Click on thumbnails for larger versions. Read more . . .
-
The 2012 annual meeting of the American Association of Pharmaceutical Scientists, which took place from October 14-18 at the McCormick Place convention center in Chicago, drew a number of inhalation and nasal specialists for the… Read more . . .
-
On October 17, MannKind Corporation announced a plan to sell 40,000,000 shares of its common stock, plus warrants to purchase up to 30,000,000 shares, in a public offering, which it said may or may not… Read more . . .
-
Market research firm Frost & Sullivan is presenting its 2012 Global Enabling Technology Award to Alexza Pharmaceuticals for its Staccato thermal vaporization inhaler platform. The award is designed to recognize a company for “developing a… Read more . . .
-
Contract manufacturer PharmaForm, a subsidiary of Akela Pharma, has announced plans to move from Austin, TX to the San Diego, CA area. The company offers formulation and manufacturing services for numerous dosage forms, including nasal… Read more . . .
-
MAP Pharmaceuticals has resubmitted its New Drug Application (NDA) for Levadex inhaled dihydroergotamine for the treatment of migraine to the FDA, the company has announced. The FDA issued a complete response letter to MAP in… Read more . . .
-
According to Chiesi Group, a Phase 1 trial of its inhaled phosphodiesterase 4 (PDE4) inhibitor for the treatment of lung diseases such as COPD and asthma demonstrated that the drug, known as CHF 6001, was… Read more . . .
-
The United States’ National Aeronautics and Space Administration (NASA) has signed a development and commercialization agreement with Epiomed Therapeutics for intranasal scopolamine. The nasal spray for the treatment of motion sickness is also called INSCOP.… Read more . . .
-
Almirall has announced that Invida Holdings has licensed the rights to market aclidinium bromide inhalers for the treatment of COPD in Australia and New Zealand. The deal covers Genuair DPIs with aclidinium alone and a… Read more . . .
-
NanoBio Corporation, which is developing a several intranasal vaccines, has announced that David Peralta will succeed James R. Baker as the company’s Chief Executive Officer after Baker was hired by Merck as Senior VP, Head… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA